Short- and long-term oral steroid therapy in patients with asthma exacerbation

Submitted: January 20, 2022
Accepted: May 17, 2022
Published: June 8, 2022
Abstract Views: 1021
PDF: 275
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Steroids are frequently used for symptom control in cases of asthma exacerbation. The aim of this study was to compare the effect of short-term and long-term oral steroid therapy on symptom control in patients with asthma exacerbation. Patients that received short-term (<10 d) and long-term (≥10 d) oral steroid therapy during asthma exacerbation were compared retrospectively. A visual analog scale (VAS) for symptom severity was administered, and the asthma control test (ACT) and pulmonary function tests were performed before and after treatment. The study included 69 patients and the overall mean duration of steroid treatment was 9.57±3.58 d (range: 5-25 d). Mean duration of short-term and long-term steroid treatment was 6.54±0.99 d and 11.63±3.21 d, respectively. Serious side-effects were not observed following oral steroid therapy. Post the short- and long-term oral steroid therapy there were not any significant differences between the 2 groups in terms of ACT, FEV1 (forced expiratory volume 1), or VAS symptom scores. The findings show that in patients with mild asthma exacerbation short-term oral steroid therapy is as effective as long-term steroid therapy and can be safely used for symptom control during periods of mild asthma exacerbation.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Wan ES, Qiu W, Baccarelli A, et al. Systemic steroid exposure is associated with differential methylation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186:1248–55. DOI: https://doi.org/10.1164/rccm.201207-1280OC
Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol 2013;9:1–25. DOI: https://doi.org/10.1186/1710-1492-9-30
Manson SC, Brown RE, Cerulli A, et al. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med 2009;103:975–94. DOI: https://doi.org/10.1016/j.rmed.2009.01.003
Shah M, Chaudhari S, McLaughlin TP, et al. Cumulative burden of oral corticosteroid adverse effects and the economic implications of corticosteroid use in patients with systemic lupus erythematosus. Clin Ther 2013;35:486–97. DOI: https://doi.org/10.1016/j.clinthera.2013.03.001
asthmacontroltest.com [Internet]. Asthma Control Test; c2020 [cited 2020 Dec 12]. Available from: https://www.asthmacontroltest.com/tr-tr/quiz/adult-quiz/
Global Initiative for Asthma (GINA). Home page; c2020 [cited 2020 Dec 12]. Available from: www.ginasthma.org
Aaron SD, Vandemheen KL, FitzGerald JM, et al. Reevaluation of diagnosis in adults with physician-diagnosed asthma. JAMA 2017;317:269–79. DOI: https://doi.org/10.1001/jama.2016.19627
Al Efraij K, Johnson KM, Wiebe D, et al. A systematic review of the adverse events and economic impact associated with oral corticosteroids in asthma. J Asthma 2019;56:1334–46. DOI: https://doi.org/10.1080/02770903.2018.1539100
Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014;371:1189–97. DOI: https://doi.org/10.1056/NEJMoa1403291
Benard-Laribiere A, Pariente A, Pambrun E, et al. Prevalence and prescription patterns of oral glucocorticoids in adults: a retrospective cross-sectional and cohort analysis in France. BMJ Open 2017;7:e015905. DOI: https://doi.org/10.1136/bmjopen-2017-015905
Berthon BS, MacDonald-Wicks LK, Wood LG. A systematic review of the effect of oral glucocorticoids on energy intake, appetite, and body weight in humans. Nutr Res 2014;34:179–90. DOI: https://doi.org/10.1016/j.nutres.2013.12.006
Bourdin A, Fabry-Vendrand C, Ostinelli J, et al. The burden of severe asthma in France: a case-control study using a medical claims database. J Allergy Clin Immunol Pract 2019;7:1477–87. DOI: https://doi.org/10.1016/j.jaip.2018.12.029
Bourdin A, Molinari N, Vachier I, et al. Mortality: a neglected outcome in OCS treated severe asthma. Eur Respir J 2017;50:1701486. DOI: https://doi.org/10.1183/13993003.01486-2017
Bleecker ER, Menzies-Gow AN, Price DB, et al. Systematic literature review of systemic corticosteroid use for asthma management. Am J Respir Crit Care Med 2020;201:276-93. DOI: https://doi.org/10.1164/rccm.201904-0903SO
Hasegawa T, Ishihara K, Takakura S, et al. Duration of systemic corticosteroids in the treatment of asthma exacerbation; a randomized study. Intern Med 2000;39:794-7. DOI: https://doi.org/10.2169/internalmedicine.39.794
Matsumoto H, Ishihara K, Hasegawa T, et al. Effects of inhaled corticosteroid and short courses of oral corticosteroids on bone mineral density in asthmatic patients: a 4-year longitudinal study. Chest 2001;120:1468–73. DOI: https://doi.org/10.1378/chest.120.5.1468
Price DB, Trudo F, Voorham J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy 2018;11:193–204. DOI: https://doi.org/10.2147/JAA.S176026
Sullivan PW, Globe G, Ghushchyan VH, et al. Exploring asthma control cutoffs and economic outcomes using the Asthma Control Questionnaire. Ann Allergy Asthma Immunol 2016;117:251-57.e2. DOI: https://doi.org/10.1016/j.anai.2016.07.020

How to Cite

Çakmak, Mehmet Erdem, Saltuk Buğra Kaya, Özge Can Bostan, Ebru Damadoğlu, Gül Karakaya, and Ali Fuat Kalyoncu. 2022. “Short- and Long-Term Oral Steroid Therapy in Patients With Asthma Exacerbation”. Monaldi Archives for Chest Disease 93 (1). https://doi.org/10.4081/monaldi.2022.2209.